ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

sapablursen

Also written as “Sapablursen” and “IONIS TMPRSS6-Lrx”.

Its studies are mostly in Polycythemia Vera · beta-Thalassemia · Thalassemia, led by 2 companies.

Drug pageSapablursen: every studyAll 4 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Aug 14, 20194 company-led studies, 1 open or runningNext primary completion: Sep 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Ionis Pharmaceuticalsits history only30 open or runningphase 2since Aug 14, 2019May 18, 2017none ahead
Ono Pharmaceutical11 open or runningphase 3since Feb 18, 2026Feb 18, 2026Sep 2028phase 3 · NCT07429266

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Ono Pharmaceutical only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Dec 19, 2020Named sapablursenINNProposed as its International Nonproprietary Name in WHO's List 124
  2. Feb 18, 2026First study: phase 3 study in Polycythemia VeraFirst studyNCT07429266 · 250 planned · United States, Australia, Austria and more

Ahead

  1. Sep 2028Primary completion: phase 3 study in Polycythemia VeraNCT07429266

TargetBeta

TMPRSS6 →read by rule
“An antisense oligonucleotide (ASO) targeting the transmembrane protease serine 6 (TMPRSS6) mRNA and ”NCIt, by rule

Other programs on TMPRSS6

ProgramCompanyFurthest phaseStudies
AG-236ruleAgios Pharmaceuticalsphase 32
Anti-TMPRSS6 Monoclonal Antibody DISC-3405ruledisc-medicine-incphase 26

Studies

The one study Ono Pharmaceutical leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07429266Polycythemia Vera · United States, Australia, Austria and more3RecruitingSep 2028250

How it is read

Names in the registry

  • “sapablursen”, 2 entries
  • “Sapablursen”, 1 entry
  • “IONIS TMPRSS6-Lrx”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.